Foundayo confers greater HbA1c reduction than Farxiga, Ozempic pill in type 2 diabetes

NEW ORLEANS — Once-daily orforglipron induced greater reductions in HbA1c than dapagliflozin and oral semaglutide for adults with type 2 diabetes, according to findings from the ACHIEVE-2 and ACHIEVE-3 trials. As Healio previously reported from the ACHIEVE-1 trial, orforglipron (Foundayo, Eli Lilly), a small molecule oral GLP-1, conferred greater decreases in HbA1c and body weight at 40 weeks